Archford Capital Strategies LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,354 shares of the company’s stock after purchasing an additional 149 shares during the period. Archford Capital Strategies LLC’s holdings in Johnson & Johnson were worth $1,349,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the company. BFT Financial Group LLC lifted its holdings in shares of Johnson & Johnson by 1.2% during the 2nd quarter. BFT Financial Group LLC now owns 5,170 shares of the company’s stock valued at $852,000 after purchasing an additional 59 shares during the last quarter. Davis Rea LTD. grew its position in shares of Johnson & Johnson by 2.3% during the 2nd quarter. Davis Rea LTD. now owns 2,666 shares of the company’s stock valued at $439,000 after acquiring an additional 60 shares during the period. White Lighthouse Investment Management Inc. boosted its holdings in Johnson & Johnson by 0.7% in the 2nd quarter. White Lighthouse Investment Management Inc. now owns 8,691 shares of the company’s stock worth $1,432,000 after buying an additional 60 shares during the last quarter. Dumont & Blake Investment Advisors LLC boosted its holdings in Johnson & Johnson by 0.3% in the 2nd quarter. Dumont & Blake Investment Advisors LLC now owns 19,337 shares of the company’s stock worth $3,186,000 after buying an additional 61 shares during the last quarter. Finally, Alta Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 2.1% in the 2nd quarter. Alta Wealth Advisors LLC now owns 3,049 shares of the company’s stock worth $502,000 after buying an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 67.14% of the company’s stock.
Several equities research analysts recently issued reports on the company. SVB Leerink reiterated a “buy” rating on shares of Johnson & Johnson in a report on Thursday, July 29th. Morgan Stanley lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 target price on the stock. in a research note on Tuesday, September 7th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 target price on the stock in a research note on Friday, October 22nd. Wells Fargo & Company reissued a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, October 7th. Finally, Raymond James decreased their target price on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 20th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $187.78.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Monday, October 18th. The company reported $2.60 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.35 by $0.25. The firm had revenue of $23.34 billion for the quarter, compared to analyst estimates of $23.72 billion. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.20 EPS. Equities research analysts predict that Johnson & Johnson will post 9.78 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 7th. Stockholders of record on Tuesday, November 23rd will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.65%. The ex-dividend date is Monday, November 22nd. Johnson & Johnson’s payout ratio is presently 63.38%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Featured Article: S&P/TSX Index
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.